High-fat diet-induced complement activation mediates intestinal inflammation and Neoplasia, independent of obesity

Molecular Cancer Research

Volumn 14, Issue 10, 2016, Pages 953-965

  Doerner, Stephanie K ^a   Reis, Edimara S ^b   Leung, Elaine S ^c   Ko, Justine S ^a   Heaney, Jason D ^d   Berger, Nathan A ^a,e   Lambris, John D ^b   Nadeau, Joseph H ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTERITIS; GASTROINTESTINAL POLYPOSIS; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; INTESTINE CANCER; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTO ONCOGENE; RISK ASSESSMENT; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; INTESTINE TUMOR; METABOLISM;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; CYTOKINES; DIET, HIGH-FAT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OBESITY; PROTO-ONCOGENES;

EID: 84991735313     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0153     Document Type: Article

References (60)

1. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015;15:484-98.
2. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med 2015;66:297-309.
3. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
4. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-45.
5. Mentor-Marcel RA, Bobe G, Barrett KG, Young MR, Albert PS, Bennink MR, et al. Inflammation-associated serum and colon markers as indicators of dietary attenuation of colon carcinogenesis in ob/ob mice. Cancer Prev Res (Phila) 2009;2:60-9.
6. Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T, Kochi T, et al. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 2011;410:108-13.
7. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40.
8. Newmark HL, Yang K, Kurihara N, Fan K, Augenlicht LH, Lipkin M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 2009;30:88-92.
9. Jiang Y, Pan Y, Rhea PR, Tan L, Gagea M, Cohen L, et al. A sucrose-enriched diet promotes tumorigenesis in mammary gland in part through the 12-lipoxygenase pathway. Cancer Res 2016;76:24-9.
10. Schulz MD, Atay C, Heringer J, Romrig FK, Schwitalla S, Aydin B, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature 2014;514:508-12.
11. Couto E, Boffetta P, Lagiou P, Ferrari P, Buckland G, Overvad K, et al. Mediterranean dietary pattern and cancer risk in the EPIC cohort. Br J Cancer 2011;104:1493-9.
12. Veldhoen M, Brucklacher-Waldert V. Dietary influences on intestinal immunity. Nat Rev Immunol 2012;12:696-708.
13. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148:1244-60e16.
14. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia causedby amutation inthe murine homolog of the APC gene. Science 1992;256:668-70.
15. Joslyn G, Carlson M, Thliveris A, Albertsen H, Gelbert L, Samowitz W, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601-13.
16. Singer JB, Hill AE, Burrage LC, Olszens KR, Song J, Justice M, et al. Genetic dissection of complex traits with chromosome substitution strains of mice. Science 2004;304:445-8.
17. Burrage LC, Baskin-Hill AE, Sinasac DS, Singer JB, Croniger CM, Kirby A, et al. Genetic resistance to diet-induced obesity in chromosome substitution strains of mice. Mamm Genome 2010;21:115-29.
18. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995;92:11490-4.
19. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996;383:86-9.
20. Lucas L, Russell A, Keast R. Molecular mechanisms of inflammation. Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal. Curr Pharm Des 2011;17:754-68.
21. Berglund ED, Li CY, Ayala JE, McGuinness OP, Wasserman DH. Regulation of endogenousglucose production inglucose transporter 4 over-expressing mice. PLoS One 2012;7:e52355.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabe-tologia 1985;28:412-9.
23. Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, et al. Pharmacological characterization of antagonists of the C5a receptor. Br J Pharmacol 1999;128:1461-6.
24. Puppa MJ, White JP, Sato S, Cairns M, Baynes JW, Carson JA. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta 2011;1812:1601-6.
25. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83.
26. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrineeffectsoftumor-derived complement.Cell Rep2014;6:1085-95.
27. Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res 2014;74:3454-65.
28. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Kou-toulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008;9:1225-35.
29. Piao C, Cai L, Qiu S, Jia L, Song W, Du J. Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-medi-ated inflammatory cell infiltration. J Biol Chem 2015;290:10667-76.
30. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev 2013;65:500-43.
31. Ueki T, Mizuno M, Uesu T, Kiso T, Nasu J, Inaba T, et al. Distribution of activated complement, C3b, and its degradedfragments, iC3b/C3dg, inthe colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996;104: 286-92.
32. Sugihara T, Kobori A, Imaeda H, Tsujikawa T, Amagase K, Takeuchi K, et al. The increased mucosal mRNA expressions of complement C3 and inter-leukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010;160: 386-93.
33. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
34. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400.
35. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 2012;18:1407-12.
36. Downs-Canner S, Magge D, Ravindranathan R, O'Malley ME, Francis L, Liu Z, et al. Complement inhibition: a novel form of immunotherapy for colon cancer. Ann Surg Oncol 2016;23:655-62.
37. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012;14:994-1004.
38. Ning C, Li YY, Wang Y, Han GC, Wang RX, Xiao H, et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1beta/IL-17A axis. Mucosal Immunol 2015;8:1275-84.
39. Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015;160:700-14.
40. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009;18:2975-88.
41. Guglietta S, Chiavelli A, Zagato E, Krieg C, Gandini S, Ravenda PS, et al. Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun 2016;7:11037.
42. Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A, Md Akhir FN, et al. The complement C3a receptor contributes to melanoma tumor-igenesis by inhibiting neutrophil and CD4+ T cell responses. J Immunol 2016;196:4783-92.
43. Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, et al. Autocrine complement inhibits IL10-dependent T-cell mediated antitumor immunity to promote tumor progression. Cancer Discov 2016 Jun 13. [Epub ahead of print].
44. Levi JS, L.M, Laurent RS, Lang A, Rayburn J. F as in Fat: how obesity threatens America's future 2012. Trust for America's Health Report http://healthyamericans.org/report/100/.2012.
45. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell 2015;161:119-32.
46. Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, et al. Dietary modulation of gut microbiota contributes to alleviation of both genetic and simple obesity in children. E Bio Medicine 2015;2:966-82.
47. Sinasac DS, Riordan JD, Spiezio SH, Yandell BS, Croniger CM, Nadeau JH. Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome. Int J Obes (Lond) 2016;40:346-55.
48. Spiezio SH, Amon LM, McMillen TS, Vick CM, Houston BA, Caldwell M, et al. Genetic determinants of atherosclerosis, obesity, and energy balance in consomic mice. Mamm Genome 2014;25:549-63.
49. Wang L, Zhang Q. Application of the Apc(Min/+) mouse model for studying inflammation-associated intestinal tumor. Biomed Pharmac-other 2015;71:216-21.
50. Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci 2014; 1311:57-76.
51. Guffey CR, Fan D, Singh UP, Murphy EA. Linking obesity to colorectal cancer: recent insights into plausible biological mechanisms. Curr Opin Clin Nutr Metab Care 2013;16:595-600.
52. Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP, et al. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol 2010;177:3180-91.
53. Kim EJ, Choi MR, Park H, Kim M, Hong JE, Lee JY, et al. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res 2011;13:R78.
54. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014;2014:149185.
55. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA 2015;112:E2487-96.
56. Chehoud C, Rafail S, Tyldsley AS, Seykora JT, Lambris JD, Grice EA. Complement modulates the cutaneous microbiome and inflammatory milieu. Proc Natl Acad Sci USA 2013;110:15061-6.
57. Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, Garcia-Martin R, Sprott D, et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol 2013;191:4367-74.
58. Unsworth DJ, Wurzner R, Brown DL, Lachmann PJ. Extracts of wheat gluten activate complement via the alternative pathway. Clin Exp Immunol 1993;94:539-43.
59. Doerner SK, Berger NA. Dietary fats as mediators of obesity, inflammation and cancer. In Dannenberg AJ, Berger NA, editors. Obesity, inflammation and cancer. New York: Springer;2013. p.99-132.
60. Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Applying complement therapeutics to rare diseases. Clin Immunol 2015;161:225-40.